User 244644

Imclone Systems: No Shame, No Gain

Hopefully, Merck Kgaa will enter the picture to make a bid. IMCL would be better off --even if it was at a lower price. They have a proven track record in getting things done.


On Aug 08 01:06 AM nova wrote:

> "IMCL still needs BMY more than BMY needs IMCL." Why? What for? Merck
> KGaA tells everybody that they were and are ready to buyout Erbitux
> franchise from BMY at any time.
>
> For the last 6 yrs, BMY did not execute any single Erbitux registration
> quality clinical trial. None. All Erbitux high quality clinical trial
> were executed by Merck KGaA.
>
> BMY's marketing of Erbitux is a total disgrace:
> - It highly overpriced Erbitux following its approval in America.
> Merck KGaA priced Erbitux at half of BMY price and sells much more
> Erbitux than BMY. Merck KGaA expects that its Erbitux sale in two
> years will exceed $2B.
> - IMCL had to create and engage its own sale force to move Erbitux
> sale.
> - The latest clinical trials indicate that Erbitux efficacy in wild-Kras
> metastatic colorectal patients is much more superior to Avastin but
> BMY has done nothing to bring this message to medical and patients
> communities.
>
> IMCL likes to get rid off BMY. Hopefully, it will happen soon.